Keji biological is pleased to obtain the clinical trial permission of GPC3 targeting car-t cells for the treatment of GPC3 positive solid tumors

January 28, 2019 / Meitong news agency / -- carsgen therapeutics, a R & D enterprise of car-t cell immunotherapy, today announced that the company is developing products-- The clinical trial application of GPC3 targeted car-t cells for the treatment of GPC3 positive solid tumors has passed the implicit license of the drug review center of the State Food and Drug Administration (acceptance No.: cxsl1700203) This approval marks a solid step in the development of car-t cell drugs This clinical trial license is also the first clinical trial license of car-t cell drugs for solid tumors in China, and also another major case in encouraging drug research and development innovation in China Dr Li Zonghai, chairman, chief executive officer and chief scientific officer of Keji biology: "it is of great significance for Keji team to obtain the first clinical trial license of car-t cell therapy for solid tumors issued by the State Food and drug administration Solid tumors such as HCC are seriously endangering the health of our people We are glad to have the opportunity to develop new car-t immunocytotherapy to help patients As always, we will continue to work hard to achieve the goal of curing the disease and saving people as soon as possible " About Keji bio, the full name of Keji bio medicine (Shanghai) Co., Ltd is the first innovative enterprise focusing on car-t immunotherapy in China The company has carried out the first car-t clinical trial for GPC3 target treatment of HCC, car-t clinical trial for EGFR / egfrv3 double target treatment of glioblastoma and car-t clinical trial for claudin 18.2 target treatment of gastric cancer and pancreatic cancer in the world In addition, the company has also carried out the clinical research of humanized CD19 car-t in the treatment of leukemia and lymphoma, and the clinical research of BCMA car-t in the treatment of multiple myeloma Source: Keji biomedical (Shanghai) Co., Ltd